Susquehanna International Group, LLP Bria Cell Therapeutics Corp. Call Options Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2023 Aug 11, 2023	SELL	$5.72 - $7.58 $5.01 Million - $6.64 Million	-876,300 Reduced 97.94%	18,400 $118,000
Q1 2023 May 16, 2023	BUY	$4.59 - $7.99 $914,787 - $1.59 Million	199,300 Added 28.66%	894,700 $6.67 Million
Q4 2022 Feb 14, 2023	BUY	$4.28 - $6.73 $386,484 - $607,719	90,300 Added 14.92%	695,400 $3.04 Million
Q3 2022 Nov 14, 2022	SELL	$3.0 - $8.31 $704,700 - $1.95 Million	-234,900 Reduced 27.96%	605,100 $3.4 Million
Q2 2022 Aug 15, 2022	BUY	$4.28 - $11.9 $459,672 - $1.28 Million	107,400 Added 14.66%	840,000 $4.85 Million
Q1 2022 May 16, 2022	BUY	$5.91 - $10.14 $606,957 - $1.04 Million	102,700 Added 16.3%	732,600 $7.43 Million
Q4 2021 Feb 14, 2022	BUY	$7.1 - $10.61 $4.47 Million - $6.68 Million	629,900 New	629,900 $5.22 Million

Ticker BCTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,518,000
Market Cap $14.9M
Description
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.